Natco Pharma reports Q4 net loss at Rs 50.5 crore
The company had posted a consolidated net profit of Rs 53 crore in the same quarter previous fiscal, Natco Pharma said in a regulatory filing.30-05-2022
30-05-2022
Q4FY22 Quarterly Result Announced for Natco Pharma Ltd.
Natco Pharma declares Q4FY22 result: NATCO Pharma has recorded consolidated total revenue of INR 2043.8 Crore for the year ended on 31st March, 2022, as against INR 2155.7 Crore for the last year. The net profit for the period, on a consolidated basis, was INR 170.0 Crore, as against INR 442.4 Crore last year. The reduction in the profit was primarily due to inventory value write-off and provision of receivables related to Covid products, with inventory value write-off of INR 232.0 Crore and provision of INR 46.0 Crore towards estimated credit loss. Export business performed well during the quarter driven by Lenalidomide sales and profit. For the fourth quarter (Q4) ended March 31st, 2022, the company recorded net revenue of INR 610.6 Crore, on a consolidated basis, as against INR 359.7 Crore during Q4, FY 2021. There was a loss for the fourth quarter period, on a consolidated basis, of INR 50.5 Crore, primarily due to inventory value write-off and provision of estimated credit losses, as against a profit of INR 53.0 Crore same quarter last year. Result PDF30-05-2022
NATCO PHARMA LTD. - 524816 - Financial Results For The Quarter And Year Ended 31St March, 2022
Financial Results for the quarter and year ended 31st March, 202230-05-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate25-05-2022
NATCO PHARMA LTD. - 524816 - Natco Pharma Ltd Has Informed The Exchange About Legal Update
Natco Pharma Ltd has informed the Exchange about Legal Update25-05-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q4 FY233 Financial Results Earnings call24-05-2022
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter And Year Ended 31St March, 2022;
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve Approval of the Audited Financial Results for the quarter and year ended 31st March, 2022;20-05-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31, 202218-05-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 37,000 Equity shares of Rs.2/- each under NATSOP201716-05-2022